Table 2: Demographic and clinical characteristics of breast cancer patients (N = 348).

Characteristicn (%)

Age at diagnosis (years)50.98 ± 10.96 (24–83)
<45110 (31.6)
45–60166 (47.7)
>6072 (20.7)

Marital status
Single35 (10.1)
Married301 (86.5)
Divorced6 (1.7)
Widowed4 (1.1)
Unknown2 (0.6)

Smoking status
Current30 (8.6)
Past15 (4.3)
Never297 (85.3)
Unknown6 (1.7)

Alcohol intake
Yes1 (0.3)
No313 (89.9)
Unknown34 (9.8)

HRT
Yes12 (3.4)
No278 (79.9)
Unknown58 (16.7)

Menopausal status
Premenopausal153 (44.0)
Postmenopausal195 (56.0)

BMI (kg/m2)29.52 ± 5.32 (15.9–45.5)
Underweight/normal64 (18.4)
Overweight118 (33.9)
Obese166 (47.7)

Family history of breast cancer in first-degree relatives
Present70 (20.1)
Absent278 (79.9)

Site of disease
Right159 (45.7)
Left180 (51.7)
Bilateral9 (2.6)

Histologic type
Invasive ductal carcinoma277 (79.6)
Invasive lobular carcinoma36 (10.3)
Other35 (10.1)

Tumor stage
I18 (5.2)
II170 (48.9)
III101 (29.0)
IV59 (17.0)

Tumor grade
I (low grade)38 (10.9)
II (intermediate grade)128 (36.8)
III (high grade)182 (52.3)

Tumor size
T1 (<2 cm)38 (10.9)
T2 (2–5 cm)220 (63.2)
T3 (>5 cm)90 (25.9)

Lymph node status
Positive249 (71.6)
Negative99 (28.4)

LVI
Identified256 (73.6)
Not identified92 (26.4)

ER status
Positive258 (74.1)
Negative90 (25.9)

PR status
Positive234 (67.2)
Negative114 (32.8)

HER2 status
Positive84 (24.1)
Negative264 (75.9)

Molecular subtype
Luminal A213 (61.2)
Luminal B52 (14.9)
HER2-positive32 (9.2)
Triple-negative51 (14.7)

Surgery
None6 (1.7)
Mastectomy318 (91.4)
Breast conservation18 (5.2)
Unknown6 (1.7)

Adjuvant chemotherapy
Yes282 (81.0)
No26 (7.5)
Unknown40 (11.5)

Mean ± SD (range). BMI, body mass index; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HRT, hormone replacement therapy; LVI, lymphovascular invasion; PR, progesterone receptor. Other histologic subtypes included were ductal carcinoma in situ (DCIS) and mixed invasive ductal and lobular carcinoma.